World News | Riley Griffin and Cristin Flanagan, Bloomberg | Thursday September 17, 2020
Eli Lilly and Co.'s experimental antibody treatment for Covid-19 reduced the rate at which symptomatic patients were hospitalized compared to a placebo, according to preliminary study results released by the company and its partner.
www.ndtv.com